Trista Morrison - Swedish Orphan Insider

Swedish Orphan Biovitrum AB -- USA Stock  

USD 18.52  0.0002  0.0011%

Vice President - Communications for North America

Ms. Trista Morrison is Vice President Communications for North America of the Company. Morrison more than 15 years in biopharmaceutical communications span corporate, reporter and agency roles. Most recently, Morrison served as director of corporate communications for Ironwood Pharmaceuticals, where she led internal, external and brand communications as the company transitioned from a research and development organization to a fully integrated commercial biotechnology company. Prior to her role at Ironwood, Morrison served as an editor and staff writer at BioWorld Today, covering breaking news and trends in the biopharmaceutical industry. Previously she served in various positions with biopharmaceuticalfocused public relations agency Porter Novelli Life Sciences . Morrison was honored as one of PR News Top Women in PR in 2017, which recognizes communicators who have made bold advances in the profession.
  President Since 2017      
46 86 97 20 00  http://www.sobi.com

Management Efficiency

The company has return on total asset (ROA) of 9.59 % which means that it generated profit of $9.59 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 19.06 % meaning that it generated $19.06 on every $100 dollars invested by stockholders.
The company has accumulated 833.91 K in total debt with debt to equity ratio (D/E) of 0.1 which may suggest the company is not taking enough advantage from borrowing. Swedish Orphan Biovitrum AB has Current Ratio of 1.72 which is within standard range for the sector.

Similar Executives

Showing few of many executives

PRESIDENT Since

Ichiro NishinoNTT DOCOMO INC
2013
Kiyohito NagataNTT DOCOMO INC
2013
Luke MielsGlaxoSmithKline plc
2017
Cesar RojasInterconexin Elctrica S A E S P
2014
Kazunori YamamotoNTT DOCOMO INC
2013
Shoji SudoNTT DOCOMO INC
2014
Abbas HussainGlaxoSmithKline plc
2014
Hal BarronGlaxoSmithKline plc
2018
Kiyohiro OhmatsuzawaNTT DOCOMO INC
2016
Andres SarmientoInterconexin Elctrica S A E S P
N/A
Phil ThomsonGlaxoSmithKline plc
2017
Osamu HirokadoNTT DOCOMO INC
2014
Daniel BonnetInterconexin Elctrica S A E S P
2018
Patrick VallanceGlaxoSmithKline plc
N/A
Roger ConnorGlaxoSmithKline plc
2013
Kei IrieNTT DOCOMO INC
2013
Carlos GaleanoInterconexin Elctrica S A E S P
N/A
Carlos LopezInterconexin Elctrica S A E S P
2014
Yoshikiyo SakaiNTT DOCOMO INC
2015
Bill LouvGlaxoSmithKline plc
2013
Claire ThomasGlaxoSmithKline plc
2008

Entity Summary

Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Sweden and internationally. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. Swedish Orphan is traded on OTC Market in USA.Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Tomtebodav?gen 23A and employs 800 people.

Swedish Orphan Biovi Leadership Team

Hans Wigzell, Director, Ph.D
Lennart Johansson, Director, MBA
Annette Clancy, Director
Trista Morrison, President
Kirsti Gjellan, President
Jorgen Winroth, VP
Milan Zdravkovic, President, Ph.D
Hans Schikan, Director
Dennis Pedersen, President
Helena Saxon, Director, MBA
Anders Edvell, Executive, MBA
Geoffrey McDonough, CEO, Ph.D
Lars Dreioee, President, MBA
Alan Raffensperger, COO
Fredrik Berg, Executive
BoGunnar Rosenbrand, Director
Adine Axen, Director
Birgitte Volck, President
MatsOlof Wallin, President
Stefan Fraenkel, President, MBA
Hakan Bjorklund, Chairman, Ph.D
Cecilia Forberg, President
Stephen James, President, Ph.D
Bo Hansen, Chairman, Ph.D
Armin Reininger, President, Ph.D
Catarina Larsson, Director
Wills HughesWilson, President
Guido Oelkers, CEO
Jeffrey Jonas, Director, Ph.D
Matthew Gantz, Director, MBA
Theresa Heggie, Director

Stock Performance Indicators

Current Sentiment - BIOVF

Swedish Orphan Biovi Investor Sentiment
Macroaxis portfolio users are unresponsive in their opinion about investing in Swedish Orphan Biovitrum AB. What is your outlook on investing in Swedish Orphan Biovitrum AB? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

BATS Exchange Efficient Frontier

Diversify in USA Market
The main assumption in equity investing is that a higher degree of volatility (or risk) means a higher potential (or expected) return on investment. Conversely, investors who take on a low degree of risk have a low expection for return.
Diversify Portfolios
You can create optimal portfolios in USA market or optimize your existing portfolio in one of two ways: 1) For any level of risk, select the one which has the highest expected return. 2) For any expected return, select the one which has the lowest volatility.
Diversify Portfolios
Check also Trending Equities. Please also try Commodity Channel Index module to use commodity channel index to analyze current equity momentum.